Wai C Wong

US Patent:

6608086, Aug 19, 2003

Filed:

Oct 5, 2001

Appl. No.:

09/972801

Inventors:

Charles Gluchowski - Wayne NJ
John M. Wetzel - Elmwood Park NJ
George Chiu - Bridgewater NJ
Mohammed R. Marzabadi - Ridgewood NJ
Wai C. Wong - Newark NJ
Dhanapalan Nagarathnam - Ramsey NJ

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

C07D40112

US Classification:

514318, 546194

Abstract:

This invention provides dihydropyridines useful for treatment of prostatic hyperplasia, inhibition of cholesterol synthesis, and/or reduction of intraocular pressure.

US Patent:

6620815, Sep 16, 2003

Filed:

Aug 10, 2000

Appl. No.:

09/636518

Inventors:

Bharat Lagu - Maywood NJ
T. G. Murali Dhar - Newark DE
Dhanapalan Nagarathnam - Ramsey NJ
Yoon T. Jeon - Ridgewood NJ
Mohammad R. Marzabadi - Ridgewood NJ
Wai C. Wong - Livingston NJ
Charles Gluchowski - Danville CA

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

A61K 31496

US Classification:

51425402, 51425401, 514326, 5142288, 514318, 514321, 514322, 544366, 544369, 544 96, 546208, 546209, 546210, 546194, 546199, 546198

Abstract:

This invention is directed to oxazolidinone compounds which are selective antagonists for human receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

US Patent:

6727257, Apr 27, 2004

Filed:

Dec 5, 2000

Appl. No.:

09/730458

Inventors:

Dhanapalan Nagarathnam - Ramsey NJ
George Chiu - Bridgewater NJ
T. G. Murali Dhar - Newark DE
Wai C. Wong - Newark NJ
Mohammad R. Marzabadi - Ridgewood NJ
Charles Gluchowski - Danville CA
Bharat Lagu - Maywood NJ
Shou Wu Miao - Edison NJ

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

C07D40106

US Classification:

5142601, 5142651, 514274, 544230, 544280, 544278, 544316, 544395

Abstract:

This invention is directed to dihydropyrimidine compounds of the following formula: wherein A is which are selective antagonists for human receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

US Patent:

6777426, Aug 17, 2004

Filed:

Aug 20, 2001

Appl. No.:

09/933106

Inventors:

Wai C. Wong - Newark NJ
Yoon T. Jeon - Ridgewood NJ
T. G. Murali Dhar - Newark DE
Charles Gluchowski - Danville CA

Assignee:

Synaptic Pharmaceutical Corporation - Paramus NJ

International Classification:

C07D23324

US Classification:

514310, 514313, 514401, 546143, 546159, 5483331

Abstract:

This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

US Patent:

6989379, Jan 24, 2006

Filed:

Apr 21, 2000

Appl. No.:

10/009849

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Wai C. Wong - Hamden CT, US
Stewart A. Noble - Wheeling IL, US
Manesh N. Desai - Nutley NJ, US

Assignee:

H. Lundbick A/S - Volby-Copenhagen

International Classification:

C07D 513/04
C07D 513/22
A61K 31/381
A61P 3/04

US Classification:

51421111, 540548, 548151, 514366

Abstract:

This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

US Patent:

7273880, Sep 25, 2007

Filed:

Jan 20, 2005

Appl. No.:

11/040328

Inventors:

Mohammad R. Marzabadi - Ridgewood NJ, US
Wai C. Wong - Hamden CT, US
Stewart A. Noble - San Diego CA, US
Yasuchika Yamaguchi - Guilford CT, US

Assignee:

H. Lunbeck A/S - Copenhagen-Valby
Novartis AG - Basel

International Classification:

A61K 31/426

US Classification:

514370

Abstract:

This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

US Patent:

20020010186, Jan 24, 2002

Filed:

May 15, 2001

Appl. No.:

09/855597

Inventors:

Wai Wong - Newark NJ, US
Bharat Lagu - Maywood NJ, US
Dhanapalan Nagarathnam - Ramsey NJ, US
Mohammad Marzabadi - Ridgewood NJ, US
Charles Gluchowski - Danville CA, US

Assignee:

Synaptic Pharmaceutical Corporation

International Classification:

A61K031/519
A61K031/506

US Classification:

514/258000, 514/269000, 544/278000, 544/315000

Abstract:

This invention is directed to dihydropyrimidine compounds which are selective antagonists for human receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

US Patent:

20050176709, Aug 11, 2005

Filed:

Apr 6, 2005

Appl. No.:

11/099960

Inventors:

Mohammad Marzabadi - Ridgewood NJ, US
Wai Wong - Hamden CT, US
Stewart Noble - San Diego CA, US
Manesh Desai - Nutley NJ, US

Assignee:

H. Lundbeck A/S - Valby-Copenhagen

International Classification:

A61K031/53
A61K031/4439
A61K031/43
C07D498/02

US Classification:

514241000, 544197000, 514366000, 514340000, 546270400, 548151000

Abstract:

This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.